Phase I Study of Intratumoral Administration of HF10, Oncolytic Herpes Simplex Virus Type 1, in Patients with Advanced Unresectable Pancreatic Cancer

Trial Profile

Phase I Study of Intratumoral Administration of HF10, Oncolytic Herpes Simplex Virus Type 1, in Patients with Advanced Unresectable Pancreatic Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 May 2016

At a glance

  • Drugs HF 10 (Primary) ; Erlotinib; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Apr 2016 Status changed from recruiting to active, no longer recruiting.
    • 30 Apr 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 18 Apr 2013 Planned initiation date changed from May 2013 to 30 Apr 2013 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top